Zymeworks has appointed Kristin Stafford as chief financial officer, effective April 1, 2026.
Stafford joins from Royalty Pharma, where she served as senior vice president and chief accounting officer since December 2018. Before that, she was vice president of finance at Royalty Pharma and chief financial officer of Biopharma Credit from 2016 to 2018. Her earlier background includes work at Ernst & Young in London focused on U.S. transactions involving European life sciences companies, external SEC reporting for iHeartMedia, and audit work at Deloitte.
Kenneth Galbraith, who is chair and chief executive officer, said the company is looking to Stafford for her experience in strategic planning, capital allocation, and complex capital markets and acquisition transactions. Stafford is also a board member at Novocure.
The announcement comes as Zymeworks continues to emphasize its asset and royalty aggregation strategy around licensed products such as Ziihera and other product candidates, including pasritamig, while advancing its broader biotherapeutics pipeline. As a result of these announcements, the company's shares have moved 1.9% on the market, and are now trading at a price of $24.69. If you want to know more, read the company's complete 8-K report here.
